Combination therapy with vascular endothelial growth factor signaling pathway inhibitors
(VSPIs) and immune checkpoint inhibitors (ICIs) has led to major improvements in cancer …

Accurate assessment of glomerular filtration rate (GFR) is crucial to guiding drug eligibility,
dosing of systemic therapy, and minimizing the risks of both undertreatment and toxicity in …

Conscious exclusion of patients with kidney disease from drug trials is a commonly accepted
practice. 1 This must change. In the United States, 37 million adults, 15% of the population …

Background The US Food and Drug Administration has prioritized efforts to expand
availability of therapies, including anticancer agents, for patients with CKD. US Food and …

Renal insufficiency and/or chronic kidney disease are common comorbidities in patients with
lung cancer, potentially affecting their prognosis. The aim of the present study was to assess …

In Part 2 of this statement from the American Society of Onco-Nephrology, we address
issues related to glomerular filtration rate (GFR) and anticancer therapies, including …

Abstract Study Objective Few data are available on the association between the use of
oxycodone in patients with chronic kidney disease (CKD) and acute respiratory conditions …

Lung cancer is the leading cause of cancer-related death worldwide, 1 with non-small cell
lung cancer (NSCLC) accounting for> 80–85% of cases. 2 In patients with lung cancer, renal …

As the second leading cause of death in the United States, 1 improving the care of people
who develop cancer is a national priority. Outcomes for people with cancer have been …

because they had kidney disease. Limiting patient access to best treatment options solely
because of the presence of kidney disease is a form of renalism. This term was first used …